ArticleBasic & clinical pharmacology & toxicology2025
'This Is My Decision': A Qualitative Study of Individuals' Perspectives on Use of Semaglutide for Weight Loss.
Article in Basic & clinical pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.International journal of qualitative studies on health and well-being · 2026Article
- A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.Scandinavian journal of primary health care · 2026Article
- Hope, hype, and high costs: Navigating glucagon-like Peptide-1 based therapy initiation among young adults.Obesity pillars · 2026Article
- Patient Knowledge of GLP-1 Receptor Agonists for Obesity and Exploration of Potential Household-Level Effects in an Urban Health System.Obesity science & practice · 2026Article
- Treatment Patterns and Experienced Effects of Semaglutide for Weight Management Among Adult Users in Denmark: A Community Pharmacy-Based Cross-Sectional Survey.Diabetes, obesity & metabolism · 2026Article
- Discontinuation of Semaglutide Therapy for Obesity Management.JAMA network open · 2026Article
- Perceptions of Glucagon-like Peptide 1 Receptor Agonists Among Individuals With Knee Osteoarthritis and Excess Weight: A Qualitative Study.ACR open rheumatology · 2026Article
- Beyond weight loss: Integrating GLP-1 RA therapies into psychological and behavioral care for obesity and binge eating disorder.Reviews in endocrine & metabolic disorders · 2026Review
- Impact of semaglutide pretreatment on reproductive outcomes in women with overweight and obesity with infertility: a real-world multicenter cohort study.Reproductive biology and endocrinology : RB&E · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Individuals using semaglutide for weight loss constitute a new, sizeable patient group, yet limited qualitative research of this group exists. Therefore, we explored their perspectives, including motivation for treatment, attitudes towards the medication and experiences with its use. Semistructured interviews with seven individuals (five women, average age 50 years, average treatment duration 9 months) were conducted, audio-recorded, transcribed verbatim and analysed using systematic text condensation. We identified three themes: 'I have absolutely run out of options', 'I am lucky to have a cooperative doctor' and 'It's the feeling of being normal'. Using semaglutide for weight loss was considered a life-changing event, as most respondents were concerned about declining physical health due to overweight. Most showed strong autonomy in managing their treatment, including delaying dose increases, reducing the dose or taking individual doses by 'counting clicks'. Our data suggest a need for more support from healthcare professionals to guide individuals using semaglutide for weight loss, particularly in dosing, monitoring and managing side effects, with an emphasis on individualized and holistic care. Further research on individuals' perspectives related to weight loss and semaglutide use is needed to maintain and improve individuals' quality of life. SUMMARY: More people are using semaglutide to lose weight, but we still know little about their experiences. To learn more, we interviewed seven users. Many saw the treatment as life-changing, having struggled with overweight and concerns about their health. It was important to them to manage the dose themselves. Some delayed increasing the dose or took less than recommended by 'counting clicks'. Our findings show that people using semaglutide for weight loss need more support from healthcare professionals-especially with dosing, side effects and personal guidance. More research is needed to better support these users and improve their quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.